208 related articles for article (PubMed ID: 31426831)
1. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma.
Gao X; Jiang P; Zhang Q; Liu Q; Jiang S; Liu L; Guo M; Cheng Q; Zheng J; Yao H
J Exp Clin Cancer Res; 2019 Aug; 38(1):362. PubMed ID: 31426831
[TBL] [Abstract][Full Text] [Related]
2. H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma.
Zhang W; Duan R; Zhang J; Cheung WKC; Gao X; Zhang R; Zhang Q; Wei M; Wang G; Zhang Q; Mei PJ; Chen HL; Kung H; Lin MC; Shen Z; Zheng J; Zhang L; Yao H
Br J Cancer; 2018 Feb; 118(4):522-533. PubMed ID: 29348487
[TBL] [Abstract][Full Text] [Related]
3. RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma.
Liang YY; Deng XB; Zeng LS; Lin XT; Shao XF; Wang B; Mo ZW; Yuan YW
Cancer Lett; 2018 Sep; 432():75-83. PubMed ID: 29864454
[TBL] [Abstract][Full Text] [Related]
4. NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway.
He W; Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Zhang T
Aging (Albany NY); 2021 May; 13(10):14015-14038. PubMed ID: 34030133
[TBL] [Abstract][Full Text] [Related]
5. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma.
Shen Z; Yang ZF; Gao Y; Li JC; Chen HX; Liu CC; Poon RT; Fan ST; Luk JM; Sze KH; Li TP; Gan RB; He ML; Kung HF; Lin MC
Cancer Res; 2008 Jan; 68(2):404-14. PubMed ID: 18199534
[TBL] [Abstract][Full Text] [Related]
6. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
[TBL] [Abstract][Full Text] [Related]
7. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
8. HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway.
Yao Y; Fang ZP; Chen H; Yue L; Min DL; Tang LN; Yu WX; Kung HF; Lin MC; Shen Z
Cancer Gene Ther; 2012 Sep; 19(9):601-8. PubMed ID: 22767217
[TBL] [Abstract][Full Text] [Related]
9. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
10. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
[TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma.
He J; He J; Min L; He Y; Guan H; Wang J; Peng X
Int J Cancer; 2020 Feb; 146(4):1052-1063. PubMed ID: 31259424
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
Ueda K; Akiba J; Ogasawara S; Todoroki K; Nakayama M; Sumi A; Kusano H; Sanada S; Suekane S; Xu K; Bae KH; Kurisawa M; Igawa T; Yano H
Acta Biomater; 2016 Jan; 29():103-111. PubMed ID: 26481041
[TBL] [Abstract][Full Text] [Related]
14. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
Alsaab HO; Sau S; Alzhrani RM; Cheriyan VT; Polin LA; Vaishampayan U; Rishi AK; Iyer AK
Biomaterials; 2018 Nov; 183():280-294. PubMed ID: 30179778
[TBL] [Abstract][Full Text] [Related]
15. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
Yuen JS; Sim MY; Siml HG; Chong TW; Lau WK; Cheng CW; Huynh H
Br J Cancer; 2011 Mar; 104(6):941-7. PubMed ID: 21407223
[TBL] [Abstract][Full Text] [Related]
17. HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma.
Li T; Liu L; Li L; Yao X; Hu X; Cheng J; Chen Z; Guo J; Li R; Ge C; Lin MC; Yao H
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794215
[TBL] [Abstract][Full Text] [Related]
18. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
20. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
Zhang L; Xie D; Lei Y; Na A; Zhu L
Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
